Evommune, Inc. EVMN · Stock Open Evommune, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
Evommune, Inc. Analysis (EVMN)
Is Evommune, Inc. a good investment? Evommune, Inc. (EVMN) is currently trading at 6.25 USD. Market analysts have a consensus price target of 24.13 USD. This suggests a potential upside from current levels.
Earnings Schedule: Evommune, Inc. is expected to release its next earnings report on Oct. 16, 2026. The market consensus estimate for Forward EPS is -3.54.
Investor FAQ
Does Evommune, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Evommune, Inc.?
Evommune, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Oct. 16, 2026. The company currently has a trailing EPS of -3.75.
Company Profile
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Community Discussion